Kane Biotech Retains GR Consulting to Identify Potential Partnerships for its Proprietary DispersinB® Wound Care Hydrogel
October 31 2019 - 6:55AM
Kane Biotech Inc. (TSX-V: KNE), (the “Corporation” or “Kane
Biotech”), a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms, is pleased to announce that
they have retained GR Consulting to develop and implement the
out-licensing strategy for their DispersinB® wound care Hydrogel
for both the United States and European markets.
“Gary and Edwin have years of experience and an exhaustive
network in the wound care space that will allow Kane to not only
accelerate the licensing of our technology, but also maximize the
value of a future licensing agreement”, said Marc Edwards, Kane
Biotech CEO.
“We’re excited to work with Kane Biotech on the future of
DispersinB®. I believe that Kane’s strategy of using this
enzyme to enhance the efficacy of products that are part of the
current standard of care will prove very attractive to potential
commercial partners”, said Gary Robinson, Principal of GR
Consulting. "We’re looking forward to help shape the future
of DispersinB®. Just the fact that peer-reviewed studies and
reviews, from 2005 to 2019, mention it as a
"thoroughly studied" "biofilm-dispersing" therapy, underlines
its potential as a therapeutic approach that can help patients",
said Dr. Edwin den Braber, Managing Partner at GR Consulting.
According to the USA National Institutes of Health (NIH),
biofilms are estimated to be responsible for 80% of all human
bacterial infections and are costly to deal with for consumers,
industry, governments and hospitals. The DispersinB® enzyme is able
to prevent and disperse many of these biofilms.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Corporation has a
portfolio of biotechnologies, intellectual property (56 patents and
patents pending, trade secrets and trademarks) and products
developed by the Corporation’s own biofilm research expertise and
acquired from leading research institutions. StrixNB(TM),
DispersinB(R), Aledex(R), bluestem(TM), AloSera(TM), coactiv+(TM)
and Kane(R) are trademarks of Kane Biotech Inc. The Corporation is
listed on the TSX Venture Exchange under the symbol "KNE".
About GR Consulting
GR Consulting (GRc) is an international healthcare
consultancy firm, providing strategic advisory services for
healthcare and life science companies. GRc has a deep
expertise in wound healing, biomaterials, implants,
regenerative medicine and
nanotechnology. Through an expansive network
of subject and industry experts
including R&D, commercial, clinical, regulatory,
reimbursement, and financial disciplines GRc has successfully
supported start-up and early stage companies to achieve
and exceed their growth expectations.
For more information, please visit
www.kanebiotech.com, or contact:
Marc EdwardsChief Executive OfficerKane Biotech
Inc.
+1 (514) 910-6991
medwards@kanebiotech.com
Ray DupuisChief Financial OfficerKane Biotech Inc.+1 (204)
298-2200
rdupuis@kanebiotech.com
Joe Green US. Investor Relations Edison Inc. +1 (646)
653-7030
jgreen@edisongroup.com
Laine YonkerUS. Investor RelationsEdison Inc. +1 (646) 653
7035
lyonker@edisongroup.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Caution Regarding Forward-Looking
Information
This press release contains certain statements regarding Kane
Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect management’s
current beliefs and are based on information currently available to
management. Certain material factors or assumptions are applied in
making forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to,
risks relating to the Company’s: (a) financial condition, including
lack of significant revenues to date and reliance on equity and
other financing; (b) business, including its early stage of
development, government regulation, market acceptance for its
products, rapid technological change and dependence on key
personnel; (c) intellectual property including the ability of the
Company to protect its intellectual property and dependence on its
strategic partners; and (d) capital structure, including its lack
of dividends on its common shares, volatility of the market price
of its common shares and public company costs. Further information
about these and other risks and uncertainties can be found in the
disclosure documents filed by the Company with applicable
securities regulatory authorities, available at www.sedar.com. The
Company cautions that the foregoing list of factors that may affect
future results is not exhaustive.
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Apr 2023 to Apr 2024